78
Participants
Start Date
July 10, 2024
Primary Completion Date
July 10, 2027
Study Completion Date
July 10, 2027
Orelabrutinib
Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
Bendamustine
Bendamustine IV will be administered as per the schedule specified in the respective arm.
Rituximab
Rituximab IV will be administered as per the schedule specified in the respective arm.
Venetoclax
Venetoclax PO will be administered as per the schedule specified in the respective arm.
RECRUITING
Ruijin Hospital, Shanghai
Third Xiangya Hospital of Central South University
UNKNOWN
Anhui Provincial Cancer Hospital
OTHER
Fujian Medical University Union Hospital
OTHER
Yantai Yuhuangding Hospital
OTHER
Huadong Hospital Affiliated with Fudan University, Shanghai
UNKNOWN
The First Affiliated Hospital of Anhui Medical University
OTHER
Jiangxi Provincial Cancer Hospital
OTHER
Fujian Cancer Hospital
OTHER_GOV
Ruijin Hospital
OTHER